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OBJECTIVE — Recent large randomized trials have linked adverse cardiovascular and cere-
brovascular events with hypoglycemia. However, the integrated physiological and vascular bi-
ological mechanisms occurring during hypoglycemia have not been extensively examined.
Therefore, the aim of this study was to determine whether2ho fmoderate clamped hypogly-
cemia could decrease ﬁbrinolytic balance and activate pro-atherothrombotic mechanisms in
individuals with type 1 diabetes and healthy individuals.
RESEARCH DESIGN AND METHODS — Thirty-ﬁve healthy volunteers (19 male and
16 female subjects age 32 2 years, BMI 26 2 kg/m
2, A1C 5.1 0.1%) and twenty-four with
type1diabetes(12maleand12femalesubjectsage333years,BMI242kg/m
2,A1C7.7
0.2%)werestudiedduringeithera2-hhyperinsulinemic(9pmol kg
1 min
1)euglycemicor
hypoglycemic (2.9  0.1 mmol/l) clamp or both protocols. Plasma glucose levels were normal-
ized overnight in type 1 diabetic subjects prior to each study.
RESULTS — Insulinlevelsweresimilar(60244pmol/l)inallfourprotocols.Glycemiawas
equivalent in both euglycemic protocols (5.2  0.1 mmol/l), and the level of hypoglycemia was
also equivalent in both type 1 diabetic subjects and healthy control subjects (2.9  0.1 mmol/l).
Using repeated ANOVA, it was determined that plasminogen activator inhibitor (PAI-1), vascu-
lar cell adhesion molecule (VCAM), intercellular adhesion molecule (ICAM), E-selectin, P-
selectin, interleukin-6 (IL-6), vascular endothelial growth factor (VEGF), and adiponectin
responses were all signiﬁcantly increased (P  0.05) during the2ho fhyperinsulinemic hypo-
glycemia as compared with euglycemia in healthy control subjects. All measures except PAI-1
were also found to be increased during hypoglycemia compared with euglycemia in type 1
diabetes.
CONCLUSIONS — In summary, moderate hypoglycemia acutely increases circulating lev-
els of PAI-1, VEGF, vascular adhesion molecules (VCAM, ICAM, E-selectin), IL-6, and markers
of platelet activation (P-selectin) in individuals with type 1 diabetes and healthy individuals. We
conclude that acute hypoglycemia can result in complex vascular effects including activation of
prothrombotic, proinﬂammatory, and pro-atherogenic mechanisms in individuals with type 1
diabetes and healthy individuals.
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H
ypoglycemia occurs very com-
monlyinindividualswithtype1di-
abetes. Despite this, the effects of
hypoglycemia on in vivo vascular biology
in type 1 diabetes have not been exten-
sively studied. Case reports and a recent
study have linked hypoglycemia with an-
gina, myocardial infarction, and acute ce-
rebrovascularevents(1,2).Morerecently,
a large epidemiological study has deter-
mined that hypoglycemia results in an in-
creased risk of cardiovascular disease and
all-cause mortality (3). Additionally, a re-
centlargerandomizedclinicaltrialintype
2 diabetes has highlighted an increased
risk of death when glucose levels are in-
tensively treated (4). Whereas the role
played by hypoglycemia in directly caus-
ing the increased adverse events in the
Action to Control Cardiovascular Risk in
Diabetes (ACCORD) trial is not estab-
lished, a much stronger link between se-
vere hypoglycemia and vascular adverse
events was indicated in the Veteran’s Af-
fairs Diabetes Trial (VADT) study (also in
type 2 diabetes) (5). As patients with type
1 diabetes advance into middle age, they
arealsolikelytobecomemoresusceptible
to vascular disease. Hypoglycemia has
been implicated with sudden death in
type 1 diabetes, although the mechanism
remains speculative (6). Offsetting this
risk, a previous period of intensive glu-
cose control combined with continued
moderate glycemic levels (A1C 8.0%)
has resulted in a reduction in cardiovas-
cular disease in type 1 diabetes (7). How-
ever,informationaddressinganypossible
proinﬂammatory and resultant activation
of pro-atherothrombotic responses in
type 1 diabetes during hypoglycemia is
scarce. To date, very few studies have in-
vestigated the effects of hypoglycemia on
vascularphysiologyintype1diabetes(8–
10). Complicating interpretation of this
scarcedataisthefactthatinsulinandglu-
cose levels were not controlled. Thus, be-
cause it is now recognized that both
insulinandhyperglycemiacanhaveinde-
pendentvascularbiologicaleffects(11),it
becomes important to strictly control
these two important variables. Therefore,
this present study has tested the hypoth-
esis that acute moderate hypoglycemia
can activate proinﬂammatory mecha-
nisms and reduce ﬁbrinolytic balance in
both individuals with type 1 diabetes and
nondiabetic individuals. The hyperinsu-
linemic euglycemic and hypoglycemic
clamp techniques were used so that insu-
lin levels could be equated and glucose
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during each study.
RESEARCH DESIGN AND
METHODS— Thirty-ﬁve healthy sub-
jects (19 male and16 female subjects, age
32 years  2, BMI 26  2 kg/m
2, A1C
5.1  0.1) and twenty-four with type 1
diabetes (12 male and12 female subjects,
age333years,BMI242kg/m
2,A1C
7.7  0.2 [normal range 4–6.5%],
diabetes duration 17  8 years) were
studied (data can be found in online ap-
pendix Table 1, available at http://
care.diabetesjournals.org/cgi/content/
full/dc09-0354/DC1). Individuals with
type 1 diabetes had normal bedside tests
of autonomic function (12) and did not
have hypoglycemia unawareness based
on the methods of Gold, et al. (13). Type
1 diabetic individuals had no major
macroormicrocomplicationsofdiabetes.
Type 1 diabetic subjects were excluded
from the study if they had a history of
hypoglycemia induced convulsions or a
major episode of hypoglycemia in the
preceding 2 years. Type 1 diabetes in-
dividuals were treated with multiple
daily insulin injections or with an insu-
lin pump. All subjects were nonsmokers
and had a normal blood count, plasma
lipids,plasmaelectrolytes,liver,andrenal
function, and were normotensive. No
subject was taking medications known to
affect neuroendocrine responses to hypo-
glycemia (speciﬁcally, ﬂuoxetine) or in-
ﬂuence platelet, clotting, or ﬁbrinolytic
balance.Someoftheindividualsincluded
in the present study had served as control
subjects to determine usual baseline
counterregulatory responses to hypogly-
cemiainpreviousstudies(14,15).Studies
were approved by the Vanderbilt Univer-
sity human subjects Institutional Review
Board, and all participants gave written
informed consent.
Subjectsparticipatedineitherasingle
hyperinsulinemiceuglycemicorhypogly-
cemic clamp or both sets of experiments.
The number of individuals participating
in each arm of the study were: type 1 di-
abetes euglycemia (n  14), type 1 diabe-
tes hypoglycemia (n  17), healthy
controleuglycemia(n22),healthycon-
trol hypoglycemia (n  25). Ten healthy
control subjects and seven individuals
with type 1 diabetes participated in both
euglycemic and hypoglycemic protocols
inarandomizedfashion.Resultsfromthis
subgroup are conceptually similar to the
entire cohort (data are available in online
appendix Table 3, Fig. A1 and A2). All
study patients were asked to avoid any
exercise and consume their usual weight-
maintaining diet for 3 days before each
experiment. All type 1 diabetic patients
were asked to perform intensive home
blood glucose monitoring (i.e., at least
four glucose tests per day) and to avoid
hypoglycemia for at least 5 days before a
study. On the day prior to a study, inter-
mediate or long-acting insulin was dis-
continued and replaced by injections of
regular insulin before breakfast and
lunch. Each subject was admitted to the
Vanderbilt General Clinical Research
Center (CRC) at 5:00 P.M. the evening
before an experiment. At this time in the
individuals with type 1 diabetes, two in-
travenous cannulae were inserted under
1% lidocaine local anesthesia. One can-
nula was placed in a retrograde fashion
into a vein on the back of the hand. This
hand was placed in a heated box (55–
60
oC)duringthestudysothatarterialized
blood could be obtained. The other can-
nula was placed in the contralateral arm
for infusions. All subjects received an
eveningmeal,andindividualswithtype1
diabetes received a continuous low-dose
infusion of insulin to normalize plasma
glucose. The insulin infusion was ad-
justed overnight to maintain blood glu-
cose between 4.4 and 7.2 mmol/l.
Hypoglycemia experiments
All subjects were studied after an over-
night, 10-h fast. Venous cannulae as de-
scribed above were placed in the healthy
control subjects. After this, a period of
120 min was allowed to elapse followed
by a 120-min hyperinsulinemic hypogly-
cemic experimental period. At time 120
min, a primed constant (9.0 pmol   kg
1  
min
1) infusion of insulin (Human Reg-
ular Insulin; Eli Lilly, Indianapolis, IN)
was started and continued until 240 min.
The rate of fall of glucose was controlled
(0.08 mmol/min), and the glucose na-
dir (2.9 mmol/l) was achieved using a
modiﬁcation of the glucose clamp tech-
nique. During the clamp period, plasma
glucose was measured every 5 min and a
20% dextrose infusion was adjusted so
that plasma glucose levels were held con-
stant at 2.9  0.1 mmol/l (16). Potassium
chloride (20 mmol/l) was infused during
the clamp to reduce insulin-induced
hypokalemia.
Euglycemia experiments
Theseexperimentsfollowedthesamefor-
mat as the above described hypoglycemia
experiments with the exception that eu-
glycemia (5.2  0.1 mmol/l) was main-
tained during each study.
Analytical methods
The collection of blood samples has been
described elsewhere (14). Plasma glucose
concentrations were measured in tripli-
cate using the glucose oxidase method
with a glucose analyzer (Beckman, Ful-
lerton, CA). Insulin was measured as
previously described with an interassay
coefﬁcient of variation (CV) of 9% (14).
Catecholamines were determined by high-
performacne liquid chromatography
with an interassay CV of 12% for epi-
nephrine and 8% for norepinephrine
(14). Cortisol was assayed using the
clinical assays -coat radioimmunoas-
saykitwithaninterassayCVof6%(14).
Nonesteriﬁed fatty acids (NEFAs) were
measured using the WAKO kit with an
interassay CV of 7%.
Blood was drawn every 60 min for
soluble vascular cell adhesion molecule-1
(sVCAM-1), soluble intercellular adhe-
sionmolecule-1(sICAM-1),E-selectin,P-
selectin, interleukin-6 (IL-6), tumor
necrosis factor- (TNF-), vascular en-
dothelial growth factor (VEGF), plasmin-
ogen activator inhibitor 1 (PAI-1), tissue
plasminogen activator (tPA), and adi-
ponectin was drawn every 60 min and
every30minforcatecholamines,cortisol,
and NEFA during the experimental pe-
riod. Vascular adhesion molecules and
adiponectin were assayed using LINCO
Research Kits (St. Charles, Missouri) with
interassay CVs of 8.5% for sVCAM, 9.7%
for sICAM, 13.4% for sE-selectin,
15.9% for adiponectin), 9.02% for IL-6,
9.98% for TNF-, and 8.2% for VEGF.
P-selectin (CV 9.9%), Meso scale discov-
ery (Gaithersburg, MD), PAI-1, and tPA
antigen were determined by TintElize
PAI-1 Kit with interassay CV of 3.3%.
Statistical analysis
Data are expressed as means  SE and
were analyzed using standard, paramet-
ric, one and two-way analysis of variance
(ANOVA) with repeated measures where
appropriate (SPSS, Chicago, IL). Data
were also analyzed with paired and un-
paired two tailed t test (Graph Pad Soft-
ware, San Diego, CA). In all cases, a P 
0.05 was accepted as statistically signiﬁ-
cant. Individual peak and nadir values
during the ﬁnal 60 min (at time 180 or
240 min) of hypoglycemia and euglyce-
mia were compared for vascular biologi-
cal parameters.
Vascular effects of hypoglycemia
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Plasma glucose was maintained equiva-
lently (5.2  0.1 mmol/l) during the eu-
glycemic clamps. Plasma glucose reached
steady state by 150 min, and equivalent
hypoglycemia (2.9  0.1 mmol/l) was
maintained during all hypoglycemia
clamp procedures (online appendix Fig.
A3). Insulin levels (602  24 pmol/l) for
both healthy and type 1 diabetes groups
were similar during all four protocol
clamp studies (online appendix Fig. A3).
Neuroendocrine counterregulatory
hormones
Epinephrine responses were signiﬁcantly
higher (P  0.001) during the ﬁnal 30
min of hypoglycemia (5.6  0.7 nmol/l,
3.14  0.5 nmol/l) as compared with eu-
glycemia (0.19  0.03 nmol/l, 0.27 
0.04 nmol/l) in both the healthy and type
1 diabetic groups, respectively. Epineph-
rine values were higher during hypogly-
cemia in healthy control subjects (P 
0.008) as compared with type 1 diabetic
subjects. Norepinephrine levels were also
signiﬁcantly higher (P  0.001) during
the ﬁnal 30 min of hypoglycemia (1.9 
0.3 nmol/l, 1.8  0.02 nmol/l) as com-
pared with euglycemia (0.90.2 nmol/l,
1.1  0.01 nmol/l) in healthy control
subjects and type 1 diabetic subjects, re-
spectively. Norepinephrine levels were
not different during hypoglycemia in
healthy control subjects and type 1 dia-
betic subjects. There was a trend for
plasma cortisol levels to be higher in
healthy control subjects as compared
with type 1 diabetic subjects (861  42
vs. 725  46 nmol/l, P  0.09). Cortisol
valueswerehigher(P0.001)duringhy-
poglycemiaascomparedwitheuglycemia
in both healthy control subjects (861 
42 vs. 357  24 nmol/l) and type 1 dia-
betic subjects (725  46 vs. 302  66
nmol/l), respectively.
Intermediary metabolism
Blood NEFA levels fell signiﬁcantly (P 
0.0001) during hypoglycemic and eugly-
cemic clamps. However, there were sig-
niﬁcantly higher levels (P 0.05) of
NEFAduringtheﬁnal30minofhypogly-
cemia as compared with euglycemia in
bothhealthycontrolsubjects(9711vs.
68  18 mol/l) and type 1 diabetic pa-
tients (100  18 vs. 50  4 mol/l),
respectively.
Atherogenic vascular adhesion
molecules
WiththeexceptionofVCAM-1inhealthy
control subjects and ICAM-1 in subjects
with type 1 diabetes, baseline values were
similar at the start of euglycemic and hy-
poglycemic clamps (online appendix Ta-
bles 2 and 3). Plasma VCAM, ICAM, and
E-selectin responses during the 120-min
clamp studies were signiﬁcantly different
(P  0.05–P  0.0001 ANOVA) during
hypoglycemia as compared with euglyce-
mia in both healthy control subjects and
type 1 diabetic subjects (Fig. 1). Individ-
ual peak values for VCAM, ICAM, and
E-selectin were increased signiﬁcantly
Figure 1—Effects of hyperinsulinemic euglycemia and hypoglycemia (2.9 mmol/l) in overnight-
fasted healthy control subjects (n  35) and individuals with type 1 diabetes (n  24) that
participated in either one or both of the studies on vascular biological markers. Response of
VCAM-1, ICAM-1, E-selectin, and VEGF are signiﬁcantly increased during hypoglycemia as
comparedwitheuglycemiainbothhealthycontrolsubjectsandtype1diabeticsubjects.Statistical
difference with two-way ANOVA during the 120-min clamp experiments is marked in each graph
panel.
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cemia (Fig. 3); mean individual nadir val-
ues of VCAM, ICAM, and E-selectin were
signiﬁcantly (P  0.05) decreased from
baselineduringeuglycemiainbothtype1
diabeticsubjectsandhealthycontrolsub-
jects(Fig.3).Themagnitudeofresponses
did not differ in healthy control subjects
and type 1 diabetic subjects.
Platelet activation and ﬁbrinolytic
balance
Plasma P-selectin responses were signiﬁ-
cantly different (P  0.05 ANOVA) dur-
ing the hypoglycemic as compared with
euglycemic clamp studies in both healthy
control subjects and type 1 diabetic sub-
jects (Fig. 2). Baseline PAI-1 levels were
signiﬁcantly different (P  0.05) in the
type 1 diabetes group (online appendix
Table3).PlasmaPAI-1valuesweresignif-
icantly different during hypoglycemia as
compared with euglycemia in healthy
control subjects but not type 1 diabetic
subjects (Fig. 2). Mean individual peak
values from baseline for P-selectin and
PAI-1 responses were increased (P 
0.05) during hypoglycemia in both
healthy control subjects and type 1 dia-
betic subjects (Fig. 3). Nadir P-selectin
and PAI-1 values were signiﬁcantly (P 
0.01) lower from baseline during hyper-
insulinemic euglycemia in both type 1 di-
abetic subjects and healthy control
subjects (Fig. 3). Plasma concentrations
of tPA did not alter during either euglyce-
mic or hypoglycemic clamps in both nor-
mal subjects and individuals with type 1
diabetes.ResponsesofP-selectin,tPAand
PAI-1weresimilarinhealthycontrolsub-
jects and type 1 diabetic subjects.
Adiponectin, VEGF, and
inﬂammatory cytokines
Baseline values for adiponectin, VEGF,
IL-6,andTNFweresimilaratthestartof
both sets of glucose clamps (online ap-
pendixTables2and3).Plasmaadiponec-
tin responses were signiﬁcantly different
(P 0.01 ANOVA) during the 120-min
hypoglycemic and euglycemic clamps in
healthy control subjects and type 1 dia-
betic subjects (Fig. 3). Mean individual
nadir values for adiponectin were signiﬁ-
cantly (P 0.05) reduced from baseline
during hyperinsulinemic euglycemia in
both subjects with type 1 diabetes and
healthy control subjects (Fig. 3). There
was a trend (P  0.06 ANOVA) for peak
adiponectin levels to increase from base-
lineduringhypoglycemiaintype1diabe-
tes (Fig. 3). VEGF and IL-6 responses
were signiﬁcantly different (P 0.04–
P  0.0004 ANOVA) during hypoglyce-
mia and euglycemia in type 1 diabetic
subjects and healthy control subjects
(Figs. 1 and 2). Nadir values for VEGF
and IL-6 were signiﬁcantly decreased
(P  0.04 – P 0.01) from baseline dur-
ing hyperinsulinemic euglycemia in both
subjects type 1 diabetes and healthy con-
trol subjects (Fig. 3). Mean individual
peak values during hypoglycemia were
increasedfrombaseline(P0.05)inboth
type 1 diabetic subjects and healthy con-
trol subjects. Peak values for TNF- in-
Figure 2—Effects of hyperinsulinemic euglycemia and hypoglycemia (2.9  0.1 mmol/l) in
overnight-fastedhealthycontrolsubjects(n35)andsubjectswithtype1diabetes(n24)that
participatedineitheroneorbothofthestudiesonvascularbiologicalmarkers.ResponsesofPAI-1,
P-selectin, IL-6, and adiponectin are signiﬁcantly increased during hypoglycemia as compared
with euglycemia in healthy control subjects. Responses of P-selectin, IL-6, and adiponectin are
signiﬁcantly increased during hypoglycemia as compared with euglycemia in type 1 diabetes.
Statistical difference with two-way ANOVA during the 120-min clamp experiments is marked in
each graph panel.
Vascular effects of hypoglycemia
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hypoglycemia in type 1 diabetic subjects
and nadir values were also signiﬁcantly
decreased (P 0.05) from baseline dur-
ing hyperinsulinemic euglycemia in
healthy control subjects. Adiponectin,
VEGF, TNF- and IL-6 responded simi-
larlyduringhypoglycemiainhealthycon-
trol subjects and type 1 diabetic subjects
(Fig. 3).
CONCLUSIONS— This study has
determined the effects of2ho fclamped
hyperinsulinemiceuglycemiaandmoder-
ate hypoglycemia on proinﬂammatory
mechanisms and ﬁbrinolytic balance in
individuals with type 1 diabetes and
healthy individuals. Our results demon-
strate that hypoglycemia can have acute
and widespread effects on vascular biol-
ogy. Hypoglycemia can 1) activate proin-
ﬂammatory mechanisms (ICAM, VCAM,
E-selectin, VEGF, IL-6), 2) increase plate-
let activation (P-selectin), and 3) simulta-
neously decrease systemic ﬁbrinolytic
balance (increase in PAI-1, no change in
tPA) in both individuals type 1 diabetes
and healthy individuals. These effects
wereofasimilarmagnitudeinthehealthy
control subjects and type 1 diabetic sub-
jects and were in contrast to the reduced
responses of the above vascular biological
mechanisms that occurred during
clamped euglycemia with equivalent
hyperinsulinemia.
In this present study, the effects of
hypoglycemia and hyperinsulinemia on
different proinﬂammatory and poten-
tially pro-atherothrombotic mechanisms
havebeendetermined.ICAM-1,VCAM-1
and E-selectin are cell surface proteins
thatareupregulatedduringinﬂammation
andincreasetheadhesionofleukocytesto
injured arterial endothelial cells, which is
a primary step in plaque formation and
subsequent atherosclerosis. Analysis of
the responses during the hyperinsuline-
mic clamps demonstrates a signiﬁcant ef-
fect of hypoglycemia to increase VCAM,
ICAM, E-selectin, and VEGF relative to
euglycemia in both healthy control sub-
jects and type 1 diabetic subjects individ-
uals. VEGF has been reported to be
pro-atheroscleroticinanimals(17).Inad-
dition,VEGFcanpotentlyincreaseprolif-
erationoftheendotheliumleadingtonew
blood vessels. Hypoglycemia also had
similar effects, increasing plasma levels of
P-selectin in both individuals with type 1
diabetes and nondiabetic individuals. P-
selectin is an adhesion molecule that is
activated by inﬂammation (18) and is ex-
pressed by both endothelial cells and
platelets. Recent work has demonstrated
that platelets are the major source of P-
selectin, and thus this molecule has been
recognized as a signiﬁcant marker of
platelet activation and increased throm-
botic mechanisms (18). PAI-1 was in-
creased during hypoglycemia relative to
euglycemia in healthy control subjects
but not subjects with type 1 diabetes.
However, individual peak values of PAI-1
were increased during hypoglycemia in
bothhealthycontrolsubjectsandsubjects
with type 1 diabetes, demonstrating that
hypoglycemia of 2.9 mmol/l can be a
stimulus for increased values of PAI-1.
Our present results demonstrate that
hypoglycemia decreases systemic ﬁbrino-
lytic balance by increasing PAI-1 levels
while maintaining tPA values. Thus, at
least two separate mechanisms for in-
Figure3—*MeanindividualpeakresponsesofVCAM-1,ICAM-1,E-selectin,VEGF,PAI-1,IL-6,
P-selectin, and adiponectin in both healthy control subjects (n  35) and subjects with type 1
diabetes (n  24) that participated in either one or both of the studies are signiﬁcantly increased
(P 0.05) compared with baseline. †Mean individual nadir responses of VCAM-1, ICAM-1,
E-selectin, VEGF, PAI-1, P-selectin, and adiponectin during hyperinsulinemic euglycemia in both
healthy control subjects and type 1 diabetic subjects are signiﬁcantly decreased (P 0.05) com-
pared with baseline.
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poglycemia in individuals with type 1
diabetes and healthy individuals. The po-
tential in vivo causes responsible for the
reduced ﬁbrinolytic balance and in-
creasedproinﬂammatorymechanismsac-
tivated by hypoglycemia are not known.
Duringhypoglycemia,awidespectrumof
physiologic responses are activated that
could have potential vascular biological
effects. To date, the role played by cat-
echolamines, the sympathetic nervous
system, and neuroendocrine hormones
on activating adhesion molecules and in-
ﬂuencing ﬁbrinolytic balance is incom-
pletely understood. One study using
cultured human adipose tissue has indi-
catedthatPAI-1levelsmaybesuppressed
by catecholamines, but increased by high
dose glucocorticoids (19). Other work
(20) has reported that epinephrine can
play a role via -2 adrenoceptor mecha-
nisms in increasing platelet activation
during hypoglycemia in both individuals
with type 2 diabetes and healthy individ-
uals. Therefore, it is possible that both in-
creasesinthehypothalamic-pituitaryaxis
and the sympathetic nervous system
could have effects to activate proinﬂam-
matory and pro-thrombotic mechanisms
during hypoglycemia.
Circulating triglycerides and NEFA
are known to decrease endothelial func-
tion and increase cellular insulin resis-
tance via nuclear factor-	B (21). NEFAs
were increased in both type 1 diabetic
subjectsandhealthycontrolsubjectsdur-
ing hypoglycemia as compared with the
euglycemia studies. This occurs princi-
pally due to the increased levels of cat-
echolamines and sympathetic nervous
system drive during hypoglycemia and
the unopposed suppressive effects of in-
sulin on lipolysis during the euglycemic
experiments. Thus, the elevated NEFA
levels remain a possible mechanism for
our ﬁndings. The cytokines, IL-6 and
TNF-, had differential responses during
hypoglycemiaandeuglycemiainboththe
type 1 diabetic subjects and healthy con-
trol subjects. IL-6 was increased during
hypoglycemia relative to euglycemia in
both groups whereas TNF- was in-
creasedduringhypoglycemiaintype1di-
abetes. The magnitude of the increase in
IL-6 during hypoglycemia in the healthy
control subjects was similar to that re-
ported in two recent studies by Dotson et
al. (22) and Razavi Nematollahi et al. (23)
Thus, it would appear that similar to
hyperglycemia, acute hypoglycemia can
also mediate its pro-atherothrombotic ef-
fects via TNF- or IL-6 pathways (21).
Nitric oxide (NO) has also been impli-
catedintheregulationofbothendothelial
and platelet-derived adhesion molecules
(24). Although not speciﬁcally addressed
in the present study, we have preliminary
data indicating that hypoglycemia im-
pairsendothelialNOfunction.Wewould
therefore suggest that NO may also be a
signiﬁcant molecular mechanism in-
volved in hypoglycemia’s vascular effects.
Adiponectin is released from adipose
tissue and is known to have powerful in-
sulin sensitizing and antiatherogenic
properties. To our knowledge, adiponec-
tin responses have not been investigated
duringhypoglycemiaintype1diabetesor
healthy volunteers. We were intrigued to
discover that hypoglycemia also in-
creased (relative to euglycemia) adi-
ponectin levels in type 1 diabetic subjects
and healthy control subjects. The signiﬁ-
cance of the ﬁnding is unclear and re-
quires further study.
We would also like to indicate that in
thispresentstudy,insulin,perse,hadsig-
niﬁcant, beneﬁcial effects on vascular
physiology. It is notable that in every case
where hypoglycemia resulted in an acti-
vation of a pathologic process, there was
an equal and opposite beneﬁcial effect
during the hyperinsulinemic euglycemic
control studies in both type 1 diabetes
and healthy individuals. Thus, our
present results would support previous
work demonstrating that insulin has anti-
inﬂammatory and antiatherogenic prop-
erties (10,21,24,25). There are some
limitations to this study. There are size-
able inter individual variations in in-
ﬂammatory and pro-atherothrombotic
vascular biomarkers. Thus, baseline val-
ues for VCAM-1 in healthy control sub-
jects and ICAM-1 and PAI-1 in subjects
with type 1 diabetes were signiﬁcantly
differentatthestartoftheeuglycemicand
hypoglycemic clamps. We do not know
the reason for these baseline differences.
One possible explanation is that not ev-
eryone in the study participated in both
euglycemic and hypoglycemic clamps.
We believe this is unlikely to be the cause
astherewasalsoasigniﬁcantdifferencein
baseline PAI-1 values in the type 1 dia-
betic subjects who participated in both
series of glucose clamps. The magnitude
of the changes of the vascular biomarkers
during hypoglycemia (and euglycemia)
are relatively modest. Thus, maximal
changes in vascular biomarkers during
hypoglycemia of 50–75% is greatly re-
duced compared with the multiple fold
increases of neuroendocrine hormones
occurring during identical hypoglycemia.
However, the ability to compare the in-
creases of the vascular biomarkers dur-
ing hyperinsulinemic hypoglycemia with
the similar decreases occurring during
hyperinsulinemic euglycemia does dem-
onstrate the independent effects of hypo-
glycemia. The clinical signiﬁcance of the
magnitude of the changes in the differing
proinﬂammatory and pro-atherothrom-
botic vascular biomarkers is yet to be es-
tablished. We only studied one level of
hypoglycemia. Thus, we cannot comment
on whether deeper hypoglycemia (i.e., less
than 2.9 mmol/l) would have induced
greaterchangesinvascularbiologicalmark-
ers. Additionally, the present study was de-
signed to study vascular physiologic
changesduringprolongedhypoglycemiaof
2 h. Therefore, we cannot determine the ef-
fects of shorter durations of hypoglycemia
(i.e., 30–45 min) on study end points.
In summary, this present study has
demonstratedthecomplexeffectsofacute
moderate hypoglycemia on ﬁbrinolytic
balance and proinﬂammatory mecha-
nisms in type 1 diabetic subjects and
healthy control subjects. Using glucose
clamps to equate insulin levels, this study
has demonstrated that hypoglycemia re-
sults in signiﬁcant increases in proinﬂam-
matory and potentially pro-atherogenic
adhesion molecules (ICAM, VCAM, E-
selectin, IL-6, VEGF) platelet activation
(P-selectin), and reduced ﬁbrinolytic bal-
ance (increased PAI-1). We conclude that
1) hypoglycemia can similarly activate a
broad spectrum of vascular biological
mechanisms in both type 1 diabetic sub-
jects and age- and weight-matched non-
diabetic control subjects, and 2) the
potentially deleterious long-term effects
of hypoglycemia on pro-atherothrom-
botic mechanisms needs further study.
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